NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. (NBY) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nby · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Hold
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.21
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.15 | ↓ 5.00% |
1-day model range: $1.12–$1.18. Peak: $1.18 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · NBY · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-11-11 | Ascendiant Capital | Maintains | Buy→Buy |
| 2023-08-11 | Ladenburg Thalmann | Maintains | Buy→Buy |
| 2022-05-20 | Ascendiant Capital | Maintains | Buy→Buy |
| 2019-09-18 | Ladenburg Thalmann | Maintains | Buy→Buy |
| 2019-03-13 | H.C. Wainwright | Downgrade ↓ | Buy→Neutral |
| 2018-03-26 | Roth Capital | Downgrade ↓ | Buy→Neutral |
| 2017-06-05 | Roth Capital | Maintains | Buy→Buy |
| 2016-03-07 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2015-04-30 | Maxim Group | Maintains | Buy→Buy |
| 2013-03-06 | Ascendiant Capital | Downgrade ↓ | Strong Buy→Buy |
Wall Street analysts have recently issued updated ratings on NovaBay Pharmaceuticals, Inc. (NBY) stock. Of the recent 11 rating actions, 0 were upgrades and 5 were downgrades. 5 analysts currently cover NBY.
Analyst Recommendation Trends
NBY analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$14M
↑ 42.3% YoY
Revenue Next Year
$14M
↓ 2.4% YoY
EPS This Year
$-173.25
EPS Next Year
$-30.45
↓ 82.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast NBY EPS of $-173.25 for the current fiscal year, based on estimates from 1 analysts. The NBY revenue forecast is $14M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NBY stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NBY price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The NBY short-term stock prediction for tomorrow is $1.15 (-5.00%).
NovaBay Pharmaceuticals, Inc. trades on AMEX under the ticker NBY. The NBY stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 40% of covering analysts.
Frequently asked questions
NBY forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month NBY price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.21.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.